TY  - JOUR
AU  - Kebir, Sied
AU  - Rauschenbach, Laurèl
AU  - Galldiks, Norbert
AU  - Schlaak, Max
AU  - Hattingen, Elke
AU  - Landsberg, Jennifer
AU  - Bundschuh, Ralph A.
AU  - Langen, Karl-Josef
AU  - Scheffler, Björn
AU  - Herrlinger, Ulrich
AU  - Glas, Martin
TI  - Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases
JO  - Neuro-Oncology
VL  - 18
IS  - 10
SN  - 1523-5866
CY  - Oxford
PB  - Oxford Univ. Press
M1  - FZJ-2016-06354
SP  - 1462 - 1464
PY  - 2016
AB  - Identifying patients with pseudoprogression, which is characterized by an initial increase of contrast-enhancing lesions that resolve or at least stabilize spontaneously on follow-up imaging without any treatment change, is critical for avoiding premature termination of potentially effective treatment. With the advent and success of checkpoint inhibitors such as ipilimumab, nivolumab, or pembrolizumab in particular, detecting pseudoprogression in patients with malignant melanoma has become a major challenge in clinical practice given a frequency as high as 7%–10% of cases.1,2 Diagnosing progressive disease and excluding pseudoprogression in melanoma metastases using the immune-related Response Criteria (irRC)2 require the initial increase of at least 25% in lesions load to be confirmed by follow-up imaging at least 4 weeks later.2 However, particularly for brain metastases from malignant melanoma, follow-up imaging might not be feasible for patients with clinical deterioration at the time of initial increase of lesions load. These patients might not be able to wait 4 weeks for a follow-up investigation to decide on 
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000386162800016
C6  - pmid:27591333
DO  - DOI:10.1093/neuonc/now154
UR  - https://juser.fz-juelich.de/record/821111
ER  -